Updates are available Correction dated 2025-12-24

Article History

Received: 12 December 2024

Accepted: 11 September 2025

First Online: 27 September 2025

Change Date: 24 December 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s12325-025-03444-9

Declarations

:

: Martin Desrosiers reports clinical trial funding from AstraZeneca, GSK, Probionase Therapies, and Sanofi, is a stock shareholder in Probionase Therapies, and is an advisory board member/consultant for Regeneron Pharmaceuticals Inc. Andrew Lane is an advisory board member for Regeneron Pharmaceuticals Inc. and Sanofi. Stella E. Lee is an advisory board member for and reports clinical trial finding from AstraZeneca, Genentech, GSK, Regeneron Pharmaceuticals Inc., and Sanofi, and reports publication support from AstraZeneca, GSK, Regeneron Pharmaceuticals Inc., and Sanofi. Eugenio De Corso is an advisory board member/consultant for and reports clinical trial funding and publication support from AstraZeneca, GSK, Novartis, and Sanofi. Scott Nash, Changming Xia, Amr Radwan, and Yamo Deniz are employees of Regeneron Pharmaceuticals Inc. and may hold stock and/or stock options in the company. Mark Corbett and Paul J. Rowe are employees of Sanofi and may hold stock and/or stock options in the company.

: The SINUS-24 and SINUS-52 studies were conducted according to the principles laid down in the Declaration of Helsinki. Institutional review boards and independent ethics committees reviewed and approved the protocols, informed consent forms, and patient information before study initiation. A full list is available in the supplementary materials.